<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505202</url>
  </required_header>
  <id_info>
    <org_study_id>2091</org_study_id>
    <nct_id>NCT04505202</nct_id>
  </id_info>
  <brief_title>Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications</brief_title>
  <official_title>Effect of Chlorhexidine-Induced Oral Care on Ventilator-Related Some Respiratory System Complications in Patients With Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karabuk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karabuk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilator-associated pneumonia and ventilator-associated treakeabronchitis in respiratory&#xD;
      tract infections associated with ventilator are common infections in intensive care unit and&#xD;
      cause significant morbidity, mortality and health expenditures in nosocomial infections.&#xD;
      Adequate and effective oral care by nurses in intensive care patients, possible&#xD;
      complications, intensive care unit stay in the intensive care unit and is very important in&#xD;
      terms of mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study will (1) evaluate the effect of 0.12% chlorhexidine gluconate on&#xD;
      ventilator-associated pneumonia, ventilator-associated treakeabronchitis, (2) determine the&#xD;
      effect of preventing microorganism colonization, and (3) assess the mortality rate for each&#xD;
      patient and the cost-effectiveness in the health expenditures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathogen colonization change</measure>
    <time_frame>change from baseline pathogen colonization at Day 3</time_frame>
    <description>We will examine microbiological analyses ( mini-BAL, oropharyngeal and tracheal secretions)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral assessment guide score change</measure>
    <time_frame>at the time of admission into the study (day 0), at study day 2 and at day 3</time_frame>
    <description>The score ranges from 8 to 24 and higher scores indicating worse oral health</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical pulmonary infection score change</measure>
    <time_frame>at the time of admission into the study (day 0), at study day 2 and at day 3</time_frame>
    <description>The score ranges from 0 to 12 (ventilator-associated pneumonia ≥ 6 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>rate of tracheobronchitis change</measure>
    <time_frame>change from baseline the rate of tracheobronchitis at Day 3</time_frame>
    <description>Questionary (use the rate of tracheobronchitis categories)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost effectiveness</measure>
    <time_frame>Day 30</time_frame>
    <description>We used the decision tree modelling for estimating the cost-effectiveness of antiseptic solutions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 7 and Day 28</time_frame>
    <description>rate of mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Tracheobronchitis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.12% chlorhexidine gluconate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sodium bicarbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12% chlorhexidine gluconate</intervention_name>
    <description>The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>sodium bicarbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Admission in critical care with in 24 hours&#xD;
&#xD;
          -  Having an endotracheal tube&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chlorhexidine allergy&#xD;
&#xD;
          -  Duration of mechanichal ventilation less than 48 h&#xD;
&#xD;
          -  Confirmed diagnosis of pneumonitis before admission in the ICU&#xD;
&#xD;
          -  Transfer from another ICU&#xD;
&#xD;
          -  Receiving chemotherapy or radiotherapy&#xD;
&#xD;
          -  Patients with immunodeficiency&#xD;
&#xD;
          -  Patients with tracheostomies&#xD;
&#xD;
          -  Required specific oral hygiene procedures&#xD;
&#xD;
          -  Facio-maxillary or dental trauma/surgery&#xD;
&#xD;
          -  Being pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karabük University Training and Research Hospital</name>
      <address>
        <city>Karabük</city>
        <state>Karabuk</state>
        <zip>78050</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karabuk University</investigator_affiliation>
    <investigator_full_name>Duygu Kes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

